Spondyloarthritis & psoriatic arthritis
Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis — data from a Portuguese registry
Authors' conclusion
Our study demonstrated that lo-axSpA is not associated with reduced treatment efficacy or compromised safety.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) treated with bDMARDs, Rheumatic Diseases Portuguese Register
- Participants
- 2,256 patients
- Exposure
- Late-onset axSpA vs early-onset axSpA on bDMARDs
- lo-axSpAn = 260
- Outcome
- bDMARD drug survival
- Follow-up
- 12 months
Methodological detailsmulticentre, national registry, Cox proportional hazards model
- Multicentre
- National registry
- Cox proportional hazards model
Main finding
As reported in the abstract
bDMARD drug survival / discontinuation
- Higher discontinuation rate in lo-axSpA during first 12 months, but lo-axSpA not associated with increased risk of therapy discontinuation
Observational data: associations, not effects.
Further findings
Disease activity (ASDAS, BASDAI, BASFI) · baseline, 3, 6 and 12 months
- Significantly higher scores in lo-axSpA at all time points; both groups showed proportional reductions over time
Reason for discontinuation
- Inefficacy was the primary reason in both groups
Original publication
Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis — data from a Portuguese registry. Rheumatology (Oxford). Published 1 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →